Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 511-522, July 2007

Avidin–biotin system: a small library of cysteine biotinylated derivatives designed for the [99mTc(N)(PNP)]2+ metal fragment

  • Cristina Bolzati

      Affiliations

    • ICIS-CNR, Corso Stati Uniti, 4, 35127 Padova, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 049 8275352; fax: +39 049 8275366.
  • ,
  • Andrea Caporale

      Affiliations

    • Department of Chemical Sciences, University of Padua, 35131 Padova, Italy
  • ,
  • Stefania Agostini

      Affiliations

    • Department of Pharmaceutical Sciences, University of Padua, 35131 Padova, Italy
  • ,
  • Davide Carta

      Affiliations

    • Department of Pharmaceutical Sciences, University of Padua, 35131 Padova, Italy
  • ,
  • Mario Cavazza-Ceccato

      Affiliations

    • Department of Pharmaceutical Sciences, University of Padua, 35131 Padova, Italy
  • ,
  • Fiorenzo Refosco

      Affiliations

    • ICIS-CNR, Corso Stati Uniti, 4, 35127 Padova, Italy
  • ,
  • Francesco Tisato

      Affiliations

    • ICIS-CNR, Corso Stati Uniti, 4, 35127 Padova, Italy
  • ,
  • Elisabetta Schievano

      Affiliations

    • Department of Chemical Sciences, University of Padua, 35131 Padova, Italy
  • ,
  • Giuliano Bandoli

      Affiliations

    • Department of Pharmaceutical Sciences, University of Padua, 35131 Padova, Italy

Received 2 October 2006; received in revised form 5 April 2007; accepted 6 April 2007. published online 13 June 2007.

Abstract 

Using the avidin–biotin system as model, we investigate here the effective application of [Tc(N)L(PNP)]+/0 technology (L=N-functionalized cysteine [O,S]; PNP=aminodiphosphine) to the preparation of target-specific radiopharmaceuticals.

A series of 99mTc-nitrido complexes containing functionalized biotin ligands was prepared and their biological profile was determined. To minimize the steric and the electronic influences of the Tc-carrying complex on the biotin–avidin receptor interaction, the following N-functionalized cysteine–biotin derivatives were synthesized: (1) Biot-CysOSH; (2) Biot-Abu-CysOSH; (3) Biot-Abz-CysOSH; (4) Biot-l-(Ac)Lys-CysOSH; (5) Biot-d-(Ac)Lys-CysOSH; (6) Biot-Glu-CysOSH.

The asymmetrical nitrido-Tc(V) 99g/99mTc(N)(Biot-X-CysOS)(PNP3) (X=spacer) complexes, where PNP3 was N,N-bis-[(dimethoxypropyl)phosphinoethyl] methoxy-ethylamine, were obtained by simultaneous addition of PNP3 and the relevant biotinylated ligand to a solution containing a 99mTc-nitrido precursor (yields >95%). In all cases, a mixture of syn- and anti isomers was observed. In vitro challenge experiments with glutathione and cysteine indicated that no transchelation reactions occurred. Assessment of the in vitro binding to avidin of the complexes revealed that only the complexes containing Biot-Abu-CysOS and Biot-Glu-CysOS ligand maintained a good affinity for the concentrator. Stability studies carried out in human and mouse plasma as well as in rat and mouse liver homogenate evidenced a rapid enzymatic degradation for the 99mTc(N)(Biot-Abu-CysOS)(PNP3) complex, whereas the 99mTc(N)(Biot-Glu-CysOS)(PNP3) one was stable in all conditions. Tissue biodistribution in normal Balb/C mice of the most stable candidate showed a rapid clearance both from the blood and the other tissues. The activity was eliminated both through the hepatobiliary system and the urinary tract.

Keywords: Avidin–biotin system, Cysteine biotinylated derivative, Technetium

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(07)00098-4

doi:10.1016/j.nucmedbio.2007.04.006

Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 511-522, July 2007